Attendees who purchased access to the AACR Annual Meeting 2014 Webcast were sent login information on May 1 - Lookup

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Introductions
F. Stephen Hodi
Dana-Farber Cancer Inst., Boston, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Regulatory Perspectives and Updates
Ke Liu
U.S. Food and Drug Administration, Rockville, MD, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Engaging an adaptive immune response in cancer
Michael A. Postow
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
A pharmaceutical development point of view
Renzo Canetta
Bristol-Myers Squibb Co., Wallingford, CT, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Melanoma Research Alliance: Investing in innovation
Louise M. Perkins
Melanoma Research Alliance, Washington, DC, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Panel Discussion
F. Stephen Hodi
Dana-Farber Cancer Inst., Boston, MA, United States
Ke Liu
U.S. Food and Drug Administration, Rockville, MD, United States
Michael A. Postow
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
Renzo Canetta
Bristol-Myers Squibb Co., Wallingford, CT, United States
Louise M. Perkins
Melanoma Research Alliance, Washington, DC, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
Plenary Session 8: Combining Immunotherapies, Immune Modulators, and Targeted Therapies: Regulatory Opportunities and Challenges
Panel: Audience Q & A
F. Stephen Hodi
Dana-Farber Cancer Inst., Boston, MA, United States
Ke Liu
U.S. Food and Drug Administration, Rockville, MD, United States
Michael A. Postow
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
Renzo Canetta
Bristol-Myers Squibb Co., Wallingford, CT, United States
Louise M. Perkins
Melanoma Research Alliance, Washington, DC, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 23, 2013 10:30 AM-12:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7